Spots Global Cancer Trial Database for An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

Official Title: Penetrating Auditory Brainstem Implant for Neurofibromatosis 2

Study ID: NCT00030043

Conditions

Neurofibromatosis 2

Interventions

Penetrating auditory brainstem implant

Study Description

Brief Summary: This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Detailed Description: Neurofibromatosis Type 2 (NF2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. Surgical resection of these tumors generally results in the transection of the VIIIth nerve, destruction of the cochlea and auditory nerve, and total hearing loss. Due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. The Auditory Brainstem Implant (ABI) provides the only available intervention to restore some auditory sensation to these patients. An ABI is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus. The PABI may be placed surgically during tumor resection. Efficacy will be assessed using psychophysical and standard speech reception measures.